Lipigon Q4 2022 - Rights issue and Progress with Lipisense
2023-03-01 10:40:00
Redeye comments on the progress of the phase I trial of Lipisense and the 2023 rights issue, which renders a new Base Case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/